Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
2.
Br J Pharmacol ; 130(5): 1183-90, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10882405

ABSTRACT

1. CGP-43182 has been described as a potent inhibitor of group IIA secreted phospholipase A(2) (group IIA sPLA(2)) activity in vitro. In rat mesangial cells, inhibition of group IIA sPLA(2) activity by CGP-43182 results in a 70% reduction of cytokine-stimulated prostaglandin E(2) biosynthesis, suggesting that group IIA sPLA(2) participates in arachidonic acid release and eicosanoid formation. Under these conditions the cytosolic phospholipase A(2) is not affected. 2. In mesangial cells, in addition to inhibition of catalytic activity, the membrane-permeant CGP-43182 completely blocked interleukin 1beta (IL1beta)-stimulated group IIA sPLA(2) gene expression. 3. A further action of CGP-43182 was a complete inhibition of cyclo-oxygenase-2 gene expression, resulting in a drastic reduction of prostaglandin formation in mesangial cells. 4. Moreover, CGP-43182 completely blocked IL1beta-induced gene expression of the inducible nitric oxide synthase, leading to an inhibition of cytokine-stimulated nitric oxide formation. 5. In contrast, the stimulatory effect of the cell-permeant cyclic AMP-analogue, dibutyryl-cAMP, on the induction of these enzymes was not inhibited by CGP-43182. These data indicate that CGP-43182 interferes with IL1beta- but not cyclic AMP-activated transcriptional regulation. 6. By studying components of the upstream transcription machinery, we observed an inhibition of NFkappaB activation by CGP-43182 in IL1beta-treated cells. Moreover, we observed that CGP-43182 prevented the phosphorylation and proteolytic degradation of the endogenous NFkappaB inhibitor, IkappaB, a process necessary for NFkappaB activation. 7. From our data, we propose that CGP-43182 is a potent anti-inflammatory drug useful for preventing the consequences of a concerted action of cytokine-stimulated pro-inflammatory genes mediated by NFkappaB.


Subject(s)
Chlorobenzenes/pharmacology , Enzyme Inhibitors/pharmacology , Gene Expression Regulation/drug effects , Glomerular Mesangium/metabolism , I-kappa B Proteins , NF-kappa B/physiology , Phospholipases A/antagonists & inhibitors , Animals , Cyclooxygenase 2 , DNA-Binding Proteins/metabolism , Epoprostenol/biosynthesis , Interleukin-1/pharmacology , Isoenzymes/biosynthesis , NF-KappaB Inhibitor alpha , Nitric Oxide/biosynthesis , Nitric Oxide Synthase/biosynthesis , Nitric Oxide Synthase Type II , Phospholipases A/genetics , Prostaglandin-Endoperoxide Synthases/biosynthesis , Rats
4.
J Pediatr Gastroenterol Nutr ; 29(2): 144-7, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10435650

ABSTRACT

BACKGROUND: The dietary intake of 63 children with insulin-dependent diabetes mellitus (IDDM; age 10 to 14 years) was weighed by dietitians for 2 days during a summer camp for youth with diabetes. Data were analyzed for the content of macronutrients with the help of a computer database program. METHODS: The dietary intake of children with diabetes was compared with that of healthy Austrian school children and with the current nutritional recommendations for children with IDDM. RESULTS: The mean intake of carbohydrate did not meet the recommended level, whereas sucrose, fiber, and protein intake approximated the recommendations. The total consumption of fat and cholesterol, however, exceeded the recommended values. The nutritional intake of Austrian children with IDDM was similar to that of healthy children of the same age and thus reflected regional dietary habits. CONCLUSION: Dietary educational measures on a national basis are needed to change harmful local eating patterns.


Subject(s)
Diabetes Mellitus, Type 1 , Diet , Adolescent , Adult , Austria , Child , Chromatography, High Pressure Liquid , Diet Surveys , Energy Intake , Female , Glycated Hemoglobin , Humans , Male , Nutrition Policy , Software
5.
J Hum Hypertens ; 13(7): 431-5, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10449205

ABSTRACT

OBJECTIVE: The role of non-invasive tests for the detection of renovascular hypertension is still a matter of controversy. The 'captopril test' is widely used; its clinical usefulness, however, remains questionable. The aim of the current study was therefore to report our own experience and to review the published data on the diagnostic significance of the test. PATIENTS AND METHODS: Data from 485 hypertensive patients who underwent a captopril test in consecutive order at our institution were analysed retrospectively. After a 30-min resting period in the supine position 50 mg of captopril was given orally. Blood was collected before and 90 min after dosage for the determination of plasma renin concentration (normal range 3.5-8.0 ng/ml/h). An increase by 100% or more of the baseline value was considered a positive response. Blood pressure was recorded at baseline and at 90 min. RESULTS: A positive response was present in 62 patients; further diagnostic work-up revealed significant renal artery stenosis in 11 of these patients. In the 423 patients with a negative response renal artery stenosis was found in three cases. With some limitations of retrospective analyses in mind, sensitivity and specificity of the test were calculated as 79% and 89%, respectively. No severe complication occurred during the test. CONCLUSION: Our data on the diagnostic indices and the safety of the captopril test are in good agreement with most published series. Altogether, available data suggest that the captopril test has a limited diagnostic accuracy as a screening test for the detection of renovascular hypertension. New radiologic non-invasive techniques with greater diagnostic value are therefore likely to challenge the clinical role of the test in the future.


Subject(s)
Angiotensin-Converting Enzyme Inhibitors , Captopril , Hypertension, Renovascular/diagnosis , Adolescent , Adult , Aged , Aged, 80 and over , Angiography , Angiotensin-Converting Enzyme Inhibitors/adverse effects , Blood Pressure/drug effects , Blood Pressure/physiology , Captopril/adverse effects , Child , Female , Humans , Hypertension, Renovascular/blood , Male , Middle Aged , Renal Artery Obstruction/diagnosis , Renin/blood , Retrospective Studies
6.
Br J Pharmacol ; 127(1): 51-6, 1999 May.
Article in English | MEDLINE | ID: mdl-10369455

ABSTRACT

Features of glomerulonephritis are expression of the inducible form of NO synthase (iNOS) as well as expression of the secretory group IIA-phospholipase A2 (sPLA2) in mesangial cells. Interleukin 1beta (IL-1beta) induces both enzymes with a similar time course resulting in an increase in nitrite production and sPLA2-IIA activity. In this study we investigated the relationship between the formation of NO and sPLA2-IIA induction in rat renal mesangial cells. Incubation of mesangial cells with the NO-donor, spermine-NONOate, for 24 h induced sPLA2-IIA mRNA expression and activity, whereas S-nitroso glutathione alone had only a small stimulatory effect. Stimulation of cells with IL-1beta caused a marked increase in sPLA2-IIA mRNA and activity that were potentiated 3 fold by both NO donors. Coincubation of cells with IL-1beta and the NOS inhibitor, L-N(G) monomethylarginine (L-NMMA), caused a dose-dependent inhibition of cytokine-induced sPLA2-IIA mRNA expression and activity. sPLA2-IIA activity was not stimulated by 8-bromo-cyclic GMP indicating that NO-induced sPLA2-IIA induction is independent of cyclic GMP-mediated signal transduction. These data show that NO contributes to the expression by cytokines of sPLA2-IIA and establishes a novel type of interaction between iNOS and sPLA2-IIA in mesangial cells. This cross-talk between inflammatory mediators may help to promote and sustain an inflammatory state in the kidney.


Subject(s)
Glomerular Mesangium/enzymology , Nitric Oxide Synthase/metabolism , Phospholipases A/metabolism , 8-Bromo Cyclic Adenosine Monophosphate/pharmacology , Animals , Blotting, Northern , Cells, Cultured , Enzyme Induction , Enzyme Inhibitors/pharmacology , Glomerular Mesangium/cytology , Interleukin-1/pharmacology , Nitric Oxide Donors/pharmacology , Nitric Oxide Synthase/antagonists & inhibitors , Nitric Oxide Synthase/biosynthesis , Nitric Oxide Synthase Type II , Nitrites/metabolism , Phospholipases A/biosynthesis , Rats , Stimulation, Chemical , omega-N-Methylarginine/pharmacology
7.
Biomed Tech (Berl) ; 43(10): 269-74, 1998 Oct.
Article in German | MEDLINE | ID: mdl-9846442

ABSTRACT

Prerequisites for the successful investigation of the mechanism of action of ESWT (extracorporeal shockwave therapy) and the establishment of treatment standards, are the ability to measure, and a knowledge of, the physical parameters involved. The most accurate measurements are obtained with laser hydrophones. Various parameters (amplitude, rise time, pulse width, pressure pulse decay, rarification phase) of a typical shock wave can thus be determined. These can then be used to calculate energy flux density, focal extent, focal volume and as well as focal energy, effective energy in a defined area, and effective biological energy. These parameters can be utilized to work out a theoretical treatment protocol.


Subject(s)
Lithotripsy/instrumentation , Quality Assurance, Health Care , Equipment Safety , Humans , Transducers, Pressure
8.
Hypertension ; 21(3): 322-8, 1993 Mar.
Article in English | MEDLINE | ID: mdl-8386700

ABSTRACT

We developed a novel method to stimulate the sympathetic innervation of the isolated, perfused rat hind limb to investigate whether a subpressor concentration of angiotensin II (Ang II) facilitates noradrenergic transmission in the vascular bed to skeletal muscle. We electrically stimulated the lumbar sympathetic trunk while perfusing the preparation with artificial medium. Seventy-five percent of the resulting frequency-dependent increases in perfusion pressure were mediated by alpha 1-adrenergic receptors. Ang II (10 nM) significantly enhanced the effects of nerve stimulation at 1 and 10 Hz (by 42% and 35%, respectively). At a supramaximal stimulation frequency (20 Hz), Ang II prolonged the duration of the response without changing the peak increase in pressure. The reuptake inhibitor cocaine did not influence the effects of Ang II at 1 and 10 Hz but blocked the effect at 20 Hz. To control for nonspecific synergism with norepinephrine, we compared Ang II with vasopressin. Both peptides potentiated the pressor response to exogenous norepinephrine; however, vasopressin did not change the pressor response to nerve stimulation at any frequency. We conclude that Ang II, but not vasopressin, facilitates noradrenergic transmission in skeletal muscle resistance vessels, independent of its direct vasoconstrictor activity. The neurovascular preparation we describe may be useful in addressing other hypotheses concerning sympathetic transmission in skeletal muscle resistance vessels.


Subject(s)
Angiotensin II/pharmacology , Sympathetic Nervous System/drug effects , Synaptic Transmission/drug effects , Animals , Arginine Vasopressin/pharmacology , Blood Pressure/drug effects , Cocaine/pharmacology , Electric Stimulation , Hindlimb/blood supply , Hindlimb/innervation , Male , Norepinephrine/pharmacology , Perfusion , Rats , Rats, Sprague-Dawley , Sympathetic Nervous System/physiology
9.
Hypertension ; 19(6 Pt 2): 687-91, 1992 Jun.
Article in English | MEDLINE | ID: mdl-1592469

ABSTRACT

Rats harboring the mouse Ren-2 transgene develop hypertension despite low levels of plasma renin activity. We tested the hypothesis that these rats exhibit an increase in vascular angiotensin formation caused by the presence of the transgene. We measured the release of angiotensins I and II from isolated perfused hindquarters by high-performance liquid chromatography and radioimmunoassay. Female rats heterozygous for the transgene had significantly elevated mean arterial pressure compared with control rats (189.3 +/- 9.5 versus 110.0 +/- 5.4 mm Hg, p less than 0.05). Plasma angiotensin II was significantly decreased in transgenic rats. Transgenic rat hindquarters released more angiotensin I (121 +/- 37 versus 39 +/- 12 fmol/30 min, n = 7 each) and more angiotensin II (210 +/- 21 versus 62 +/- 12 fmol/30 min, p less than 0.05, n = 7 each) than control rat hindquarters. Captopril increased angiotensin I release and decreased angiotensin II values in both transgenic and control rat hindquarters. Bilateral nephrectomy 24 hours before hindquarter perfusion greatly reduced angiotensin release from control rat hindquarters but not from transgenic rat hind limbs. We also tested for the presence of Ren-2 messenger RNA in mesenteric and aortic tissue by RNase protection assay and Northern blot analysis. We found that Ren-2 messenger RNA was present in mesenteric and aortic tissue of transgenic but not of control rats. We conclude that the Ren-2 transgene is expressed in vascular tissue of transgenic rats and may be responsible for substantial increases in vascular angiotensin formation.


Subject(s)
Angiotensin II/biosynthesis , Blood Vessels/metabolism , Mice, Transgenic/genetics , Mice/genetics , Renin/genetics , Angiotensin II/metabolism , Animals , Blood Pressure , Female , Hindlimb/blood supply , In Vitro Techniques , Mice, Transgenic/metabolism , Mice, Transgenic/physiology , Nephrectomy , Perfusion , RNA, Messenger/metabolism , Rats , Rats, Inbred Strains
SELECTION OF CITATIONS
SEARCH DETAIL
...